banner

World Congress on Parkinson's disease & Related Disorders
15 Nov 2013
Britannia Pharmaceuticals is pleased to announce our final congress in 2013, the XX World Congress on Parkinson’s disease and Related Disorders running from 8-11 December 2013 in Geneva, Switzerland.
Read more

AM IMPAKT - New clinical trial investigates apomorphine injection for resolving debilitating morning akinesia in Parkinson's disease patients
16 Apr 2013
AM IMPAKT, short for Apokyn for Motor IMProvement of Morning AKinesia Trial, is a Phase IV, multi-center, open-label study investigating treatment with APOKYN (APO-go/Apomine) injection to achieve rapid and reliable improvement of motor symptoms in Parkinson’s disease (PD) patients who experience delayed onset of their oral levodopa medication taken upon awakening.
Read more

Britannia Pharmaceuticals launch theparkinsonhub
11 Apr 2013
World Parkinson’s Day 2013 sees the official launch of theparkinsonhub (www.theparkinsonhub.com), an innovative, interactive resource for patients and carers. theparkinsonhub, developed by Britannia Pharmaceuticals, is committed to sharing the latest news and best practice about Parkinson’s disease (PD), with an emphasis on and around mid to late stage PD.
Read more

New International Marketing Director for Britannia Pharmaceuticals Ltd
30 Mar 2013
Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets.
Read more